Sareum Holdings PLC
09 November 2004
For immediate release 9 November 2004
SAREUM HOLDINGS PLC
("Sareum" or the "Company")
Sareum Announces Protein Expression and Structure Determination
Collaboration with Inpharmatica
Sareum Holdings plc (AIM: SAR), the structure-based drug discovery and services
business admitted to AIM in October 2004, has entered into a collaborative
agreement with Inpharmatica Ltd. to express and determine the structures of
novel, genomics-derived Nuclear Receptor protein targets to support
Inpharmatica's drug discovery programmes.
This collaboration represents a major new deal for the recently floated Company
and is on a fee-for-service basis. Under the terms of the agreement, Sareum will
receive significant upfront and substantial success payments and options to
include further targets in the future, potentially representing more than 60% of
the budgeted revenues for the current financial year to 30 June 2005.
Sareum will utilise its skills and high-throughput processes to clone, express
and purify several of Inpharmatica's Nuclear Receptor targets and progress these
through structure determination. Nuclear Receptors are an important family of
druggable proteins of high therapeutic relevance in atherosclerosis, metabolic
diseases, oncology, inflammation, and central nervous system disorders.
Commenting on the agreement, Sareum's Chief Executive Officer, Dr Tim Mitchell,
said: "We are delighted to be providing drug discovery services to Inpharmatica.
The contract marks our first as a quoted company. Our expertise in
high-throughput protein expression is particularly suited to the progression of
these novel genomics targets and I look forward to a very successful outcome."
Commenting on the agreement, Inpharmatica's Chief Executive Officer, Dr Malcolm
Weir, said: "We are very pleased to be using Sareum's high-throughput
technologies to drive our internal drug discovery forward. The potential
structural information gained from this collaboration will significantly enhance
our ability to understand their function and optimise novel drug candidates
against these very important Nuclear Receptor targets."
For further information:
Sareum Holdings 01223 497700
Tim Mitchell, Chief Executive Officer
Buchanan Communications 020 7466 5000
Mark Court, Mary-Jane Johnson
About Sareum Holdings plc
Sareum Holdings plc is a structure based drug discovery business headquartered
in Cambridge, UK. The Company was formed in August 2003 to discover new drugs
for the treatment of cancer and inflammation and to provide a range of drug
discovery services to the pharmaceutical industry. Sareum's unique approach aims
to halve the time it takes to discover new drug candidates.
Structure-based drug discovery involves the determination of a disease causing
protein's three-dimensional structure. Once the structure is known, novel
chemical entities are designed to 'lock-in' to the protein with the aim of
reversing or arresting a disease's progression.
Sareum's approach to structure based drug discovery is to produce multiple
recombinant proteins primarily through a baculovirus expression system;
determine their structure using x-ray crystallography; and then use the
Company's computational chemistry expertise to create virtual, focused libraries
of new chemical entities designed to interact with the target protein. Sareum
then uses its high-throughput medicinal chemistry platform to rapidly synthesise
these molecules and develop the most promising into potential drug candidates.
Sareum offers its accelerated drug discovery capabilities on a fee basis to the
pharmaceutical and biotechnology industries. Sareum intends to license out its
internally generated drug candidates at the Phase I or Phase II clinical trials
stage.
Sareum joined the Alternative Investment Market of the London Stock Exchange in
October 2004 and trades under the symbol SAR. For further information, please
visit www.sareum.co.uk
About Inpharmatica
Founded in 1998, Inpharmatica Ltd is a selective drug discovery company using
predictive technologies to improve speed and productivity. Focusing on highly
druggable targets, its unique proprietary platform, PharmaCartaTM, is an
integrated suite of informatics-based technologies fully capable of gene to
candidate operations. Inpharmatica's lead discovery programme is focused on
generating pre-clinical candidates against 16 novel Nuclear Receptors - proteins
widely considered to be both druggable and of high therapeutic interest. Other
significant programmes include novel secreted proteins/antibody targets, ion
channels, P450 enzymes, metalloproteinases and progestin receptors.
Inpharmatica's initial technology was based on research from Professor Janet
Thornton's group at University College London. The Company employs approximately
100 professionals at its UK locations in London and Cambridge, with business
development headed in North America. Inpharmatica has raised some £35.0m from
leading venture capitalists and has sales/collaboration partnerships with
Serono, Pfizer, GSK, Aventis, Daiichi, Riken, Taisho, UCB Pharma, MDL, Ionix,
CellZome and Galapagos.
This information is provided by RNS
The company news service from the London Stock Exchange
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial
intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may
contain inaccuracies, outdated information, or subjective interpretations. This content is intended
for general informational purposes only and should not be considered professional advice or factual
confirmation.
We encourage you to independently verify any information provided,
especially if it will be relied upon for making decisions or taking action. Any reliance you place
on this material is strictly at your own risk. The AI system that produced this content cannot
assess the specifics of individual circumstances, and results may vary based on context and
individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
Create an Account
Create your FREE account to receive personalised announcements, watchlists, market updates, investment insights and new features.
Personalise your experience
Tell us a little about yourself to receive personalised content, announcements and relevant investment opportunities.